% 0期刊文章%卡罗琳·莫罗% Arnaud Delval %一个阿兰Destee凯西雅% %一个瑞吉斯朱尔茨博尔代% Luc Defebvre %大卫•狄维士%法国Parkgait-II研究小组% T哌醋甲酯在晚期帕金森患者步态和注意力障碍与丘脑下的刺激:一项多中心随机、双盲、安慰剂对照研究(S02.004) % D J神经病学2012% % P S02.004-S02.004 % V 78% N 1补充% X目的:评价哌醋甲酯的功效(MPD)治疗的步态和注意力障碍非痴呆晚期帕金森病(PD)患者与丘脑核刺激和温和的每日剂量左旋多巴。首页背景步态障碍的治疗管理是令人失望的。提出了冻结步态导致一部分去甲肾上腺素和多巴胺的减少和随后的失衡。MPD增强突触纹状体和皮质突触前的多巴胺和去甲肾上腺素转运体抑制水平。开放的研究表明积极影响步态但最近的一项安慰剂对照,双盲研究小样本的先进高患者每日剂量左旋多巴等价物没有STN刺激显示没有好处。设计/方法:八十例非精神错乱与PD和中度到重度的步态障碍筛选3个月的安慰剂对照,双盲多中心研究有两个平行的武器(临床试验N°)。丘脑下的刺激是所有研究期间保持不变。主要结果测量指标是改变站坐走测试(慢波睡眠,时间)组在12周。次要结果措施包括冻结在雾轨迹,运动机能的变化,以UPDRS, gait-diary冻结发作,注意表演、行为、认知和心脏宽容。重复测量方差分析是用来分析组间变化。结果:与PD六十九合格受试者完成了试验。我们发现显著减少步骤在慢波睡眠的时间和数量,数量的冻结在雾轨迹和日记,马达UPDRS MPD组和反应时间与控制。全球宽容是好的,但一个心脏dysrythmia恶化和一个发作。Conclusions: MPD improved gait and motor symptoms in advanced PD population under STN stimulation and moderate daily dose of levodopa.Supported by: - PHRC grants from the French Ministry of Research.- Novartis provided the methylphenidate.Disclosure: Dr. Moreau has nothing to disclose. Dr. Delval has nothing to disclose. Dr. Dujardin has nothing to disclose. Dr. Destee has received personal compensation for activities with Novartis and the French Ministry of Research. Dr. Bordet has nothing to disclose. Dr. Defebvre has nothing to disclose. Dr. Devos has received personal compensation for activities with Novartis and Aguettant. Dr. Devos has received personal compensation for activities with Novartis and Aguettant.Tuesday, April 24 2012, 13:00 pm-14:45 pm %U